BioImpacts

metrics 2024

Advancing the frontiers of biochemistry and medicine.

Introduction

BioImpacts, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, is a prominent platform dedicated to advancing the fields of Biochemistry, Genetics, Molecular Biology, Medicine, and Pharmaceutical Science. Established in 2011, this Open Access journal ensures that vital research findings are freely accessible to the global academic community. With an impressive presence in the Scopus database, BioImpacts currently holds a Q2 quartile ranking in its respective categories, reflecting its contribution to scientific discourse and its importance as a critical resource for researchers and practitioners alike. The journal's dynamic scope encompasses a wide range of topics, highlighting innovative research that addresses contemporary challenges in health and disease. Operating out of Tabriz, Iran, BioImpacts is committed to fostering interdisciplinary collaboration and knowledge dissemination through their dedicated publication efforts, which span from 2011 to 2024. Researchers, professionals, and students are encouraged to explore the rich content and cutting-edge studies presented in this journal, making it an indispensable resource in the scientific community.

Metrics 2024

SCIMAGO Journal Rank0.55
Journal Impact Factor2.20
Journal Impact Factor (5 years)2.90
H-Index47
Journal IF Without Self2.20
Eigen Factor0.00
Normal Eigen Factor0.17
Influence0.46
Immediacy Index0.50
Cited Half Life6.00
Citing Half Life7.00
JCI0.75
Total Documents458
WOS Total Citations1209
SCIMAGO Total Citations3129
SCIMAGO SELF Citations176
Scopus Journal Rank0.55
Cites / Document (2 Years)2.41
Cites / Document (3 Years)2.64
Cites / Document (4 Years)2.74

Metrics History

Rank 2024

Scopus

General Medicine in Medicine
Rank #107/636
Percentile 83.18
Quartile Q1
General Biochemistry, Genetics and Molecular Biology in Biochemistry, Genetics and Molecular Biology
Rank #82/221
Percentile 62.90
Quartile Q2
Pharmaceutical Science in Pharmacology, Toxicology and Pharmaceutics
Rank #71/183
Percentile 61.20
Quartile Q2

IF (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 204/354
Percentile 42.50
Quartile Q3

JCI (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 144/354
Percentile 59.32
Quartile Q2

Quartile History

Similar Journals

Biomolecules & Therapeutics

Elevating Research Standards in Biomolecular Science
Publisher: KOREAN SOC APPLIED PHARMACOLOGYISSN: 1976-9148Frequency: 4 issues/year

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH

Fostering Collaboration in Health and Biology
Publisher: ASSOC BRAS DIVULG CIENTIFICAISSN: 0100-879XFrequency: 12 issues/year

The BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, published by the ASSOC BRAS DIVULG CIENTIFICA, serves as a vital platform for the dissemination of cutting-edge research in the fields of medicine and biological sciences. With an ISSN of 0100-879X and E-ISSN 1414-431X, this Open Access journal has been championing free access to vital scientific knowledge since 1997. It is indexed in Scopus with notable rankings across various disciplines, including a rank of #131 in General Medicine (79th percentile) and #20 in Pharmacology, Toxicology, and Pharmaceutics (75th percentile). Covering a broad scope of topics, the journal primarily focuses on areas such as biochemistry, biophysics, immunology, neuroscience, and physiology, with a commendable categorization of Q2 and Q3 quartiles for several relevant fields in 2023. Through its commitment to high-quality research and robust peer review processes, the journal not only consolidates its reputation within the academic community but also significantly contributes to the enhancement of scientific knowledge and innovation in Brazil and beyond. Researchers, professionals, and students will find an invaluable resource in this journal, which is pivotal for those looking to stay abreast of the latest developments in medical and biological research.

Journal of Biomedical Research

Innovating Research, Transforming Medicine
Publisher: NANJING MEDICAL UNIVISSN: 1674-8301Frequency: 6 issues/year

Journal of Biomedical Research, published by Nanjing Medical University in China, is a prominent platform for groundbreaking discoveries in the fields of Biochemistry, Genetics, and Molecular Biology, as well as Medicine. With an ISSN of 1674-8301 and an E-ISSN of 1876-4819, the journal offers a vital opportunity for researchers, professionals, and students to disseminate insightful research findings. Although not currently available as an open access journal, its inclusion in the second quartile of both Biochemistry and Medicine categories underscores its growing influence and commitment to high-quality scholarship, as evidenced by its historical compliance with Scopus rankings prior to 2009. By fostering an interdisciplinary approach, the Journal of Biomedical Research aims to bridge gaps in current biomedical understanding and encourages innovative research that can lead to significant contributions in improving health outcomes. Its editorial policies guarantee rigorous peer review, making it a trusted source of knowledge in the biomedical community.

BMB Reports

Advancing the Frontiers of Biochemistry and Molecular Biology
Publisher: KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGYISSN: 1976-6696Frequency: 12 issues/year

BMB Reports is a distinguished open-access journal published by the Korean Society of Biochemistry & Molecular Biology since 2008, making significant contributions to the fields of biochemistry, molecular biology, and medicine. With a current impact factor that positions it in the Q2 category for Biochemistry and Q1 for Miscellaneous Medicine, this journal supports a wide dissemination of high-quality research findings, fostering robust dialogue among researchers, professionals, and students alike. Based in Seoul, South Korea, BMB Reports aims to publish innovative studies that advance our understanding of biochemical and molecular processes, thus shaping the future of health and medicine. The journal's commitment to open access enhances the visibility of its articles, allowing for greater accessibility and engagement in the scientific community. With notable rankings in both the Biochemistry and Molecular Biology categories, BMB Reports stands as a vital resource for those seeking to stay at the forefront of research in these rapidly evolving disciplines.

CURRENT DRUG TARGETS

Elevating Drug Discovery to New Heights
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-4501Frequency: 16 issues/year

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

JOURNAL OF GENE MEDICINE

Elevating Standards in Gene Medicine Research
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Acta Naturae

Fostering Scientific Dialogue in Biochemical Research
Publisher: RUSSIAN FEDERATION AGENCY SCIENCE & INNOVATIONISSN: 2075-8251Frequency: 4 issues/year

Acta Naturae is a peer-reviewed scientific journal published by the Russian Federation Agency for Science & Innovation, focusing on the dynamic fields of Biochemistry, Biotechnology, Molecular Biology, and Molecular Medicine. Launched in 2013, the journal has established a solid reputation in the academic community, with its articles contributing to essential advancements and discussions within these disciplines. By 2023, it has achieved notable rankings—including Q2 status in Biotechnology and Q3 in Biochemistry, Molecular Biology, and Molecular Medicine—indicating its growing influence and relevance in the scientific literature. While currently operating under a non-open access model, Acta Naturae invites researchers, professionals, and students to engage with its comprehensive research reports and reviews that span the breadth of molecular life sciences. With the aim of facilitating scientific dialogue and innovation, this journal serves as a key resource for those seeking to stay at the forefront of molecular research.

BMC Molecular and Cell Biology

Fostering collaboration in the realm of molecular and cell science.
Publisher: BMCISSN: Frequency: 1 issue/year

BMC Molecular and Cell Biology is a forward-thinking open-access journal published by BMC, specializing in the vital fields of molecular biology and cell biology. Since its inception in 2019, the journal has carved a niche for itself, ranking in the Q3 quartile in both Cell Biology and Molecular Biology categories as of 2023. With an ISSN of N/A and an E-ISSN of 2661-8850, the journal provides a platform for groundbreaking research, high-quality reviews, and innovative methodologies. Situated in the United Kingdom, BMC Molecular and Cell Biology promotes a diverse range of studies, addressing fundamental questions in biology that resonate with both experts and new researchers alike. The journal's commitment to open access ensures that valuable findings are readily available to the global scientific community, fostering collaboration and knowledge-sharing across disciplines. Researchers aiming to contribute to the field of cell and molecular biology will find this journal an indispensable resource for both publishing and staying informed on the latest advances.

Recent Patents on Anti-Cancer Drug Discovery

Pioneering Research for a Cancer-Free Future
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1574-8928Frequency: 4 issues/year

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

FASEB BioAdvances

Transforming Insights into Impactful Research
Publisher: WILEYISSN: Frequency: 12 issues/year

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.